Posts Tagged ‘drug screening’

An interview with bioengineering pioneer Kevin Healy

Author: Hamideh Emrani, 01/05/16

In the fourth in her series on “What drives research in the field of biomaterials?” blogger Hamideh Emrani interviews Professor Kevin E. Healy at the University of California, Berkeley. You can catch up on Hamideh’s earlier interviews here. I met Professor Kevin Healy at the University of California, Berkeley. He is the Jan Fandrianto Distinguished…Read more

Right Turn: Back to school and being brilliant

Author: Stacey Johnson, 09/04/15

. It’s September. I can almost hear the school bells ringing. I can definitely feel excitement in the air. For many, back to school isn’t something to dread: just the opposite; it’s something to get excited about. Tests and homework and waking up early aren’t much fun, but learning and discovering are a huge high…Read more

Avoiding ‘wrinkles in time’: Using tissue engineered grafts to model skin aging

Author: Holly Wobma, 08/06/15

. This is not a blog about cosmology, nor the space-time continuum or our place in the universe. As much as I love these deep topics, today I’d like to discuss something, quite literally, more superficial: the aging of human skin. As with other organs in our body, skin undergoes many changes as we get…Read more

Highlights from The Business of Regenerative Medicine Course

Author: Mark Curtis, 07/21/14

. The Centre for Commercialization of Regenerative Medicine (CCRM) just finished hosting the 7th annual Business of Regenerative Medicine course here in Toronto, which saw many notable figures in the space come to weigh-in on a number of critical issues relevant to commercialization in the world of regenerative medicine and cell therapy (RM).   The…Read more

Right Turn: Prof. Molly Shoichet shares her views on commercialization

Author: Stacey Johnson, 05/16/14

. Last November, I wrote about CCRM’s new Regenerative Medicine Video Network and featured an original video with Dr. Stephen Minger, Chief Scientist, Cellular Sciences GE Healthcare Life Sciences in the UK. If you enjoyed his industry perspective and insights on exciting developments and commercialization in the regenerative medicine field, I think you’ll be equally…Read more

Cell lines, patient samples, and cultures – oh my!

Author: Sara M. Nolte, 04/08/14

> The thing that is so intriguing about cancer stem cells (CSCs), from a cancer researcher’s perspective, is their powerful potential as therapeutic targets. While CSCs can create or regenerate tumours (causing relapse in some patients despite our best efforts to prevent it – more on this in my previous post on CSCs), they also…Read more

Regenerative Medicine Deal Review: December

Author: Mark Curtis, 01/13/14

. Welcome to your Regenerative Medicine Deal Review for the month of December. Toronto-based Stem Cell Therapeutics successfully executed on a financing of $33 million, while Pluristem announces it is moving forward on a licensing agreement with Korea-based CHA. Cellular Dynamics International is back in the news this month with another collaboration, this time to…Read more

Will stem cells eventually outperform pharmaceuticals or will they come to Big Pharma’s rescue?

Author: Angela C. H. McDonald, 09/11/12

You don’t have to follow pharmaceutical industry news to know that this summer has been a disappointing one for Alzheimer’s research. Many major media outlets covered the failure of potential Alzheimer’s drug bapineuzumab (Pfizer/Johnson & Johnson) in Phase II/III clinical trials, announced earlier this summer. Another disappointment came late last month with the report of…Read more

Airway epithelial cells created from human patients could provide a powerful drug-screening tool for Cystic Fibrosis

Author: Angela C. H. McDonald, 08/30/12

If you tuned into the evening news on Monday night (at least here in Canada), you would have seen my PhD supervisor Janet Rossant, discussing a recent advancement in stem cell differentiation. Amy Wong, post-doctoral fellow in the Rossant lab, created a protocol for differentiating human pluripotent stem cells into mature airway epithelial cells. The…Read more

Till & McCulloch Meetings 2012: Lessons to learn from leukemic stem cells

Author: Guest, 05/07/12

  by Alexey Bersenev The first plenary session of the Till & McCulloch Meetings was dedicated to cancer stem cells. John Dick opened the session by asking a question: “Stem cells in cancer: do they matter?” He is always ahead of time, very precise and innovative and I think cancer stem cell researchers can learn…Read more